Literature DB >> 29674325

ADCY9 (Adenylate Cyclase Type 9) Inactivation Protects From Atherosclerosis Only in the Absence of CETP (Cholesteryl Ester Transfer Protein).

Yohann Rautureau1, Vanessa Deschambault1, Marie-Ève Higgins1, Daniel Rivas1, Mélanie Mecteau1, Pascale Geoffroy1, Géraldine Miquel1, Kurunradeth Uy1, Rocio Sanchez1, Véronique Lavoie1, Geneviève Brand1, Audrey Nault1, Pierre-Marc Williams1, Maria Laura Suarez1, Nolwenn Merlet1, Line Lapointe1, Natacha Duquette1, Marc-Antoine Gillis1, Samaneh Samami1, Gaétan Mayer1,2, Philippe Pouliot3, Adeline Raignault1, Foued Maafi1, Mathieu R Brodeur1, Sylvie Levesque4, Marie-Claude Guertin4, Marie-Pierre Dubé5, Éric Thorin1,6, David Rhainds1, Éric Rhéaume1,7, Jean-Claude Tardif1,7.   

Abstract

BACKGROUND: Pharmacogenomic studies have shown that ADCY9 genotype determines the effects of the CETP (cholesteryl ester transfer protein) inhibitor dalcetrapib on cardiovascular events and atherosclerosis imaging. The underlying mechanisms responsible for the interactions between ADCY9 and CETP activity have not yet been determined.
METHODS: Adcy9-inactivated ( Adcy9Gt/Gt) and wild-type (WT) mice, that were or not transgenic for the CETP gene (CETPtg Adcy9Gt/Gt and CETPtg Adcy9WT), were submitted to an atherogenic protocol (injection of an AAV8 [adeno-associated virus serotype 8] expressing a PCSK9 [proprotein convertase subtilisin/kexin type 9] gain-of-function variant and 0.75% cholesterol diet for 16 weeks). Atherosclerosis, vasorelaxation, telemetry, and adipose tissue magnetic resonance imaging were evaluated.
RESULTS: Adcy9Gt/Gt mice had a 65% reduction in aortic atherosclerosis compared to WT ( P<0.01). CD68 (cluster of differentiation 68)-positive macrophage accumulation and proliferation in plaques were reduced in Adcy9Gt/Gt mice compared to WT animals ( P<0.05 for both). Femoral artery endothelial-dependent vasorelaxation was improved in Adcy9Gt/Gt mice (versus WT, P<0.01). Selective pharmacological blockade showed that the nitric oxide, cyclooxygenase, and endothelial-dependent hyperpolarization pathways were all responsible for the improvement of vasodilatation in Adcy9Gt/Gt ( P<0.01 for all). Aortic endothelium from Adcy9Gt/Gt mice allowed significantly less adhesion of splenocytes compared to WT ( P<0.05). Adcy9Gt/Gt mice gained more weight than WT with the atherogenic diet; this was associated with an increase in whole body adipose tissue volume ( P<0.01 for both). Feed efficiency was increased in Adcy9Gt/Gt compared to WT mice ( P<0.01), which was accompanied by prolonged cardiac RR interval ( P<0.05) and improved nocturnal heart rate variability ( P=0.0572). Adcy9 inactivation-induced effects on atherosclerosis, endothelial function, weight gain, adipose tissue volume, and feed efficiency were lost in CETPtg Adcy9Gt/Gt mice ( P>0.05 versus CETPtg Adcy9WT).
CONCLUSIONS: Adcy9 inactivation protects against atherosclerosis, but only in the absence of CETP activity. This atheroprotection may be explained by decreased macrophage accumulation and proliferation in the arterial wall, and improved endothelial function and autonomic tone.

Entities:  

Keywords:  atherosclerosis; autonomic nervous system; body weight; cholesteryl ester transfer protein; endothelium

Mesh:

Substances:

Year:  2018        PMID: 29674325     DOI: 10.1161/CIRCULATIONAHA.117.031134

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  12 in total

1.  Genome-wide discovery of genetic loci that uncouple excess adiposity from its comorbidities.

Authors:  Lam O Huang; Alexander Rauch; Eugenia Mazzaferro; Michael Preuss; Stefania Carobbio; Cigdem S Bayrak; Nathalie Chami; Zhe Wang; Ursula M Schick; Nancy Yang; Yuval Itan; Antonio Vidal-Puig; Marcel den Hoed; Susanne Mandrup; Tuomas O Kilpeläinen; Ruth J F Loos
Journal:  Nat Metab       Date:  2021-02-22

2.  High Density Lipoproteins: Is There a Comeback as a Therapeutic Target?

Authors:  Arnold von Eckardstein
Journal:  Handb Exp Pharmacol       Date:  2022

3.  Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial.

Authors:  Jean Claude Tardif; Marc A Pfeffer; Simon Kouz; Wolfgang Koenig; Aldo P Maggioni; John J V McMurray; Vincent Mooser; David D Waters; Jean C Grégoire; Philippe L L'Allier; J Wouter Jukema; Harvey D White; Therese Heinonen; Donald M Black; Fouzia Laghrissi-Thode; Sylvie Levesque; Marie Claude Guertin; Marie Pierre Dubé
Journal:  Eur Heart J       Date:  2022-10-14       Impact factor: 35.855

4.  Leveraging the local genetic structure for trans-ancestry association mapping.

Authors:  Jiashun Xiao; Mingxuan Cai; Xinyi Yu; Xianghong Hu; Gang Chen; Xiang Wan; Can Yang
Journal:  Am J Hum Genet       Date:  2022-06-16       Impact factor: 11.043

Review 5.  Pharmacogenomics.

Authors:  Dan M Roden; Howard L McLeod; Mary V Relling; Marc S Williams; George A Mensah; Josh F Peterson; Sara L Van Driest
Journal:  Lancet       Date:  2019-08-05       Impact factor: 79.321

6.  Association of DNA methylation and transcriptome reveals epigenetic etiology of heart failure.

Authors:  Zhongxiao Lin; Jishuo Chang; Xinzhi Li; Jianglin Wang; Xiaodan Wu; Xiaoyan Liu; YiZhun Zhu; Xi-Yong Yu
Journal:  Funct Integr Genomics       Date:  2021-12-06       Impact factor: 3.410

7.  A sex-specific evolutionary interaction between ADCY9 and CETP.

Authors:  Isabel Gamache; Marc-André Legault; Jean-Christophe Grenier; Rocio Sanchez; Eric Rhéaume; Samira Asgari; Amina Barhdadi; Yassamin Feroz Zada; Holly Trochet; Yang Luo; Leonid Lecca; Megan Murray; Soumya Raychaudhuri; Jean-Claude Tardif; Marie-Pierre Dubé; Julie Hussin
Journal:  Elife       Date:  2021-10-05       Impact factor: 8.140

Review 8.  Physiological roles of mammalian transmembrane adenylyl cyclase isoforms.

Authors:  Katrina F Ostrom; Justin E LaVigne; Tarsis F Brust; Roland Seifert; Carmen W Dessauer; Val J Watts; Rennolds S Ostrom
Journal:  Physiol Rev       Date:  2021-10-26       Impact factor: 37.312

9.  Role of the ADCY9 gene in cardiac abnormalities of the Rubinstein-Taybi syndrome.

Authors:  Yueheng Wu; Yu Xia; Ping Li; Hui-Qi Qu; Yichuan Liu; Yongchao Yang; Jijin Lin; Meng Zheng; Lifeng Tian; Zhuanbin Wu; Shufang Huang; Xianyu Qin; Xianwu Zhou; Shaoxian Chen; Yanying Liu; Yonghua Wang; Xiaofeng Li; Hanshi Zeng; Hakon Hakonarson; Jian Zhuang
Journal:  Orphanet J Rare Dis       Date:  2020-04-22       Impact factor: 4.123

10.  Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular Medicine.

Authors:  David Rhainds; Chris J Packard; Mathieu R Brodeur; Eric J Niesor; Frank M Sacks; J Wouter Jukema; R Scott Wright; David D Waters; Therese Heinonen; Donald M Black; Fouzia Laghrissi-Thode; Marie-Pierre Dubé; Marc A Pfeffer; Jean-Claude Tardif
Journal:  Circ Genom Precis Med       Date:  2021-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.